The updating of knowledge is more efficient if it is based on practice. This program not only offers you the best theoretical contents, but also the possibility of putting them into practice in a prestigious hospital center"

The multiple cases of hematological cancers have forced scientists to focus on this area in order to address their afflictions. The study of hematology and hemacytometry techniques are evolving rapidly thanks to tools such as immunotherapy treatments, in which many new monoclonal antibodies inhibiting lymphocyte cellular immunotolerance to the tumor are being found.

The clinical labor market demands specialists who can apply the latest scientific developments in this field. These experts must not only deal with hematological malignancies, but must also be familiar with all the techniques for the diagnosis of iron deficiency and anemias, the administration of direct-acting oral anticoagulants of iron deficiency and anemias, administration of Direct Acting Oral Anticoagulants-ACOD, bone marrow transplantation and research focused on obtaining artificial blood as a long-term solution. All this with the aim of that hematologists include these methods in the health care of international health systems.

Advances in Hematology and Hemotherapy has developed this qualification in detail, thanks to the contribution of experts in the field, who have been qualified in the field of hemostasis, coagulation laboratories, the area of hospitalization and hematopoietic transplantation, clinical trials in hematology, regenerative medicine and stem cells. The teaching team will transmit the theoretical knowledge in the first instance to the specialists so that, in the second period of the program, they can put it into practice in a hospital center.

Thanks to the practical stay in a recognized clinic, hematologists will develop in depth their practical skills when confronted with real cases. TECH proposes this teaching model, given the need for specialists to be taught rigorously and directly in the space in which they carry out their professional careers.

In addition, TECH offers a simple study based on 100% online and downloadable content that specialists can rely on at any time and place, even after completing the qualification. It is an effective methodology that will allow for an adequate and flexible academic provision, so that it can be adapted to the personal and professional needs of hematology experts.

It is part of an online methodology that will facilitate your knowledge to plan your development as a professional in blood disorders"

This Hybrid Master's Degree in Advances in Hematology and Hemotherapy contains the most complete and up-to-date educational program on the market. The most important features include:

• Development of more than 100 clinical cases developed by experts in hematology and hemotherapy who will transmit their experience to the specialists taking this program
• The graphic, schematic, and practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice
• Assessment tests for primary and secondary hemostasis, interpretation of prothrombin, thrombin and activated thromboplastin times; use of thromoelastography; mastering and interpretation of fibrinolysis tests: mediators of tissue reperfusion; diagnosis of hemophilia and monitoring monitoring of coagulation in patients with critical bleeding disorders
• Mastery and knowledge of platelet bleeding disorders
• Diagnosis and new treatments for Waldenström macroglobulinemia
• New Developments in the General Treatment of Hematologic Diseases
• Diagnosis and Treatment of Hemolytic Disease in Fetuses and Newborns
• All of this will be complemented by theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection
• In addition, you will be able to carry out a clinical internship in one of the best hospitals in the world

Broaden your professional experience with the collaboration of teachers and experts in the lymphatic area who will guide you in the study with the guarantee of their rigorousness"

In this proposed Hybrid Master's Degree, of a professionalizing nature and blended learning modality, the program is aimed at the updating of hematologists who perform their functions in hemotherapy units and require a high level of qualification. The contents are based on the latest scientific evidence, and oriented in a didactic way to integrate theoretical knowledge into clinical practice, and the theoretical-practical elements will facilitate the updating of knowledge and facilitate decision making in the face of patients' pathologies.

Thanks to their multimedia content developed with the latest educational technology, they will allow the medical professional to learn in a contextual and situated learning environment, that is, a simulated environment that will provide immersive learning programmed to train in real situations. The design of this program is centered on Problem Based Learning, by means of which the student must try to solve the different situations of professional practice that arise throughout the program. For this purpose, the student will be assisted by an innovative interactive video system created by renowned experts.

This  Hybrid Master's Degree will allow you to practice hematology in real environments, which will provide an immersive learning experience designed to face daily clinical situations"

Update your knowledge through the Hybrid Master's Degree in Advances in Hematology and Hemotherapy, in a practical and flexible way that adapts to your needs"

The contents of this program have been carefully designed by highly experienced specialists in the sector, who endorse its syllabus. Thanks to the distribution of knowledge, the specialist will learn about the role of hematopoietic cells, biopathology, the development of laboratory techniques in cytogenetics and molecular biology, advances in anemias, as well as spinal cord disorders and the physiology of hemostasis, among other aspects. From the first module, the expert will expand his knowledge of the innate and adaptive immune system, in addition to exploring new developments in megakaryopoiesis and thrombopoiesis and cell cultures and cytokines. All this, supported by a team that guarantees its study. 

It explores specialized laboratory techniques such as the use of autoanalyzers, cytochemical techniques and bone marrow aspirate”

Module 1. Recent Discoveries in Hematopoiesis, Cytogenetics and Immunophenotyping in Hematology

1.1. Current role of the multipotent hematopoietic cell, progenitor cells, growth factors and cytokines

1.1.1. Hematopoietic Stem Cells: Characteristics and Functions
1.1.2. Progenitor Cells
1.1.3. Hematopoietic Growth Factors
1.1.4. Cytokines

1.2. Biopathology of Granulopoiesis and Monocytopoiesis

1.2.1. Biopathology of Granulopoiesis
1.2.2. Biopathology of Monocytopoiesis

1.3. Advances in the Structure and Function of Lymphoid Tissue

1.3.1. Structure of the Lymphoid Tissue
1.3.2. Types of Lymphoid Tissue
1.3.3. Function of Lymphoid Tissue

1.4. Immune System Current Events. Development, Regulation, and Activation of B and T Cells

1.4.1. Development and Regulation of the Innate Immune System
1.4.2. Development and Regulation of the Adaptive Immune System
1.4.3. Immune System Functions
1.4.4. Immunosuppression

1.5. Differentiation Antigens: Latest Findings

1.5.1. Types of Differentiation Antigens
1.5.2. Physiology
1.5.3. Diagnostic Utilities

1.6. New Developments in Megakaryopoiesis and Thrombopoiesis

1.6.1. Biology of Megakaryopoiesis
1.6.2. Biology of Thrombopoiesis

1.7. Cell culture and cytokines update

1.7.1. Types of Cell Cultures
1.7.2. Cell Culture Biology
1.7.3. Cell Culture Uses
1.7.4. Cytokines and their Role in Cell Differentiation

Module 2. Update on the Importance of Laboratories in Hematology and Hemotherapy

2.1. Development of Specialized Laboratory Techniques in Recent Years

2.1.1. Handling of Autoanalyzers
2.1.2. Cytomorphology of Peripheral Blood
2.1.3. Bone Marrow Cytomorphology. Cytochemical Techniques. Bone Marrow Aspiration, Medulogram

2.2. Diagnostic Techniques of Anemic Syndrome: Recent Advances

2.2.1. Hemoglobin and hematocrit
2.2.2. Peripheral Lamina
2.2.3. Reticulocyte Count
2.2.4. Hemolysis Tests
2.2.5. Other Tests for Studying Anemias

2.3. Flow Cytometry in the Diagnosis of Hematologic Diseases

2.3.1. Fundamentals and Methodology of the Cytometry Technique
2.3.2. Usefulness in the Diagnosis of Hematologic Diseases

2.4. Basic Cytogenetic and Molecular Biology Techniques

2.4.1. Principles of Cytogenetics
2.4.2. Cytogenetics and Genetic Rearrangements in Hematologic Diseases
2.4.3. Cytogenetic Techniques
2.4.4. Principles and Techniques of Molecular Biology in Hematology

2.5. New Techniques of Hemostasis and Thrombosis

2.5.1. Tests that Measure the Functioning of Primary Hemostasis
2.5.2. Tests that Measure the Functioning of Secondary Hemostasis
2.5.3. Evidence of Physiological Inhibitors of Coagulation

2.6. Immunohematology Techniques: Present and Future

2.6.1. Basis and Methodology of Immunohematology Techniques
2.6.2. Usefulness for Diagnosing Hematologic Diseases

2.7. Therapeutic Apheresis Techniques: Current Developments

2.7.1. Plasmapheresis
2.7.2. Leukoapheresis
2.7.3. Erythroapheresis
2.7.4. Thrombocytapheresis

2.8. Current techniques for the collection, manipulation and preservation of hematopoietic progenitors of hematopoietic progenitors

2.8.1. Progenitor Cell Donor Selection
2.8.2. Progenitor Mobilization in Autologous and Healthy Donor
2.8.3. Apheresis of Hemopoietic Progenitors in Autologous and Allogeneic Transplantation
2.8.4. Bone Marrow Extraction by Surgical Procedure
2.8.5. Lymphocyte Collection: Procedure, Indications, Complications
2.8.6. Product Suitability Tests: Minimum Cellularity, Viability, Microbiological Studies
2.8.7. Progenitor Infusion: Procedure and Complications

Module 3. Anemia Update

3.1. Mechanism of Erythropoiesis, Erythroid Differentiation and Maturation.

3.1.1. Biopathology and Physiopathology of Erythrocytes
3.1.2. Structure and Types of Hemoglobin
3.1.3. Functions of Hemoglobin

3.2. Classification of Erythrocyte Disorders and Clinical Manifestations

3.2.1. Classification of Erythrocyte Disorders
3.2.2. Symptoms and Signs of Anemia by Organ Systems

3.3. Pure Red Cell Aplasia

3.3.1. Concept
3.3.2. Etiology
3.3.3. Clinical Manifestations
3.3.4. Diagnosis
3.3.5. Current Treatment Alternatives

3.4. Congenital Dyserythropoietic Anemias

3.4.1. Concept
3.4.2. Etiology
3.4.3. Clinical Manifestations
3.4.4. Diagnosis
3.4.5. Current Treatments.

3.5. Iron deficiency anemia and disturbances in iron metabolism and iron overload: current management

3.5.1. Concept
3.5.2. Classification and Etiology
3.5.3. Clinical Picture
3.5.4. Staged Diagnosis of Iron Disorders
3.5.5. Treatment Variants of Iron Disorders

3.6. Megaloblastic Anemias: Recent Advances

3.6.1. Concept
3.6.2. Classification and Etiology
3.6.3. Clinical Picture
3.6.4. Diagnostic Approach.
3.6.5. Current Treatment Schemes and Recommendations

3.7. Hemolytic Anemias: From Laboratory to Clinic

3.7.1. Concept
3.7.2. Classification and Etiology
3.7.3. Clinical Picture
3.7.4. Diagnostic Challenges
3.7.5. Alternative Treatments

3.8. Hemoglobin Disorder Anemias

3.8.1. Concept
3.8.2. Classification and Etiology
3.8.3. Clinical Picture
3.8.4. Analytical Diagnostic Challenges
3.8.5. Treatment Variants

Module 4. Scientific Developments in Spinal Cord Disorders

4.1. Medullary Aplasia

4.1.1. Definition
4.1.2. Epidemiology and Etiology
4.1.3. Clinical Manifestations
4.1.4. Clinical and Staged Diagnosis according to Diagnostic Tests
4.1.5. Latest Treatment Recommendations

4.2. Myelodysplastic Syndromes: Latest Classifications

4.2.1. Definition
4.2.2. Epidemiology
4.2.3. Clinical Manifestations
4.2.4. Diagnosis and Current Classifications
4.2.5. Current Review of the Treatment and Use of Hypomethylating Therapy

4.3. Updated Approach to Agranulocytosis

4.3.1. Definition
4.3.2. Epidemiology and Etiology
4.3.3. Clinical Manifestations
4.3.4. Diagnostic Complexities
4.3.5. New Developments in Treatment 

4.4. Polycythemia Vera

4.4.1. Definition
4.4.2. Epidemiology
4.4.3. Clinical Manifestations
4.4.4. Diagnosis
4.4.5. Current Treatment Alternatives

4.5. Essential Thrombocythemia

4.5.1. Definition
4.5.2. Epidemiology
4.5.3. Clinical Manifestations
4.5.4. Diagnosis
4.5.5. Treatment Review

4.6. Chronic Idiopathic Myelofibrosis

4.6.1. Definition
4.6.2. Epidemiology
4.6.3. Clinical Manifestations
4.6.4. Diagnosis
4.6.5. Therapeutic Approaches

4.7. Hypereosinophilic Syndrome

4.7.1. Definition
4.7.2. Epidemiology
4.7.3. Clinical Manifestations
4.7.4. Diagnostic Complexities
4.7.5. Treatment: Literature Review

4.8. Mastocytosis

4.8.1. Definition
4.8.2. Epidemiology
4.8.3. Clinical Manifestations
4.8.4. Use of Diagnostic Tests
4.8.5. Alternative Treatments.

Module 5. Current Events in Hemostasis Physiology

5.1. Update on the Biopathology of Hemostasis Types

5.1.1. Primary Hemostasis
5.1.2. Secondary Hemostasis

5.2. Advances in Vascular Endothelium Biology and Functions

5.2.1. Vascular Endothelium Biology
5.2.2. Vascular Endothelium Functions
5.2.3. Main Vascular Endothelial Mediators
5.2.4. Endothelial Dysfunction

5.3. Platelets and their Role in Coagulation: Recent Discoveries

5.3.1. Platelet Formation
5.3.2. Platelet Functions and Mediators
5.3.3. Platelets in Hemostasis

5.4. Plasma Factors and the Coagulation Cascade: From Research to the Clinic

5.4.1. Synthesis and Structure of Coagulation Factors
5.4.2. Functions of Plasma Coagulation Factors in the Coagulation Cascade
5.4.3. Coagulation Factor Deficiency

5.5. Cofactors Necessary for Blood Coagulation

5.5.1. Vitamin K and Coagulation
5.5.2. Prekallikrein
5.5.3. High Molecular Weight Cininogen
5.5.4. Von Willebrand Factor

5.6. Physiological Inhibitors of Coagulation

5.6.1. Antithrombin
5.6.2. Protein C - Protein S System
5.6.3. Antitrypsins
5.6.4. Antiplasmins
5.6.5. Other Coagulation Inhibitor Proteins

5.7. Current Events in Pregnancy and Hemostasis

5.7.1. Hemostasis Changes during Pregnancy
5.7.2. Fibrinolysis Changes during Pregnancy

5.8. New Developments in Hemostasis in Hepatic Insufficiency and Renal Insufficiency

5.8.1. Acute Hepatic Insufficiency and Hemostatic Disorders
5.8.2. Chronic Hepatic Insufficiency and Hemostatic Disorders
5.8.3. Hemostasis in Chronic Kidney Disease
5.8.4. Hemostasis in Patients with Renal Function Replacement Treatment

Module 6. Update on Coagulation, Thrombosis, and Fibrinolysis Tests

6.1. Primary and Secondary Hemostasis Evaluation Tests

6.1.1. Tests to Assess the Role of the Vascular Endothelium
6.1.2. Tests to Assess the Role of Platelets in Hemostasis
6.1.3. Tests that Assess the Role of Coagulation Factors in the Enzymatic Cascade

6.2. Interpretation of Prothrombin, Thrombin, and Activated Thromboplastin Times

6.2.1. Prothrombin Time Interpretation
6.2.2. Thrombin Time Interpretation
6.2.3. Interpretation of Activated Thromboplastin Time

6.3. Usefulness of Thromboelastography: Its Current Role

6.3.1. Definition
6.3.2. Use
6.3.3. Interpretation

6.4. Fibrinolysis Tests: The Mediators of Tissue Reperfusion

6.4.1. Tests that Assess Fibrinolysis
6.4.2. Uses
6.4.3. Interpretation

6.5. Diagnosis of Hemophilia: Traditional and the Latest Techniques

6.5.1. Types of Hemophilia
6.5.2. Tests to Diagnose Hemophilia

6.6. Monitoring Coagulation in Patients with Critical Bleeding Disorders

6.6.1. Hemostasis in Critically Ill Patients
6.6.2. Tests for Monitoring Bleeding Disorders in Critically Ill Patients

6.7. Laboratory Monitoring of Patients on Oral Anticoagulants

6.7.1. Traditional and New Oral Anticoagulants
6.7.2. Evidence for the follow-up of patients on direct oral anticoagulants 

6.8. Laboratory Monitoring in Patients Treated with Heparins

6.8.1. Heparins in Anticoagulant Treatment
6.8.2. Tests for Monitoring Heparin Treatment

Module 7. New Developments in Major Bleeding Disorders

7.1. Vascular Hemorrhagic Disorders

7.1.1. Definition
7.1.2. Epidemiology
7.1.3. Clinical Manifestations
7.1.4. Diagnostic Difficulties
7.1.5. Treatment Developments

7.2. Platelet Hemorrhagic Disorders

7.2.1. Definition
7.2.2. Epidemiology and Etiology
7.2.3. Clinical Manifestations
7.2.4. Diagnostic Complexities
7.2.5. New Treatment Approaches

7.3. Hemophilia

7.3.1. Definition
7.3.2. Epidemiology
7.3.3. Clinical Manifestations
7.3.4. Diagnosis
7.3.5. Treatment and Current Issues in Electrical Therapy

7.4. Von Willebrand Disease: Diagnostic and Therapeutic Challenge

7.4.1. Definition
7.4.2. Epidemiology
7.4.3. Clinical Manifestations
7.4.4. Diagnosis by Screening Tests
7.4.5. Treatment

7.5. Hemorrhagic Disorders due to Vitamin K Deficiency

7.5.1. Definition
7.5.2. Epidemiology
7.5.3. Clinical Manifestations
7.5.4. Etiological Diagnosis
7.5.5. Treatment Plans

7.6. Hemorrhagic Disorders due to Excess Anticoagulants

7.6.1. Definition
7.6.2. Epidemiology
7.6.3. Clinical Manifestations
7.6.4. Diagnostic Tests
7.6.5. Treatment Complexities

7.7. Acquired Hemorrhagic Disorders

7.7.1. Definition
7.7.2. Epidemiology
7.7.3. Clinical Manifestations
7.7.4. Diagnosis: The Role of Necessary Tests
7.7.5. Treatment

7.8. Disseminated Intravascular Coagulation: Recent Findings

7.8.1. Definition
7.8.2. Epidemiology and Etiology
7.8.3. Clinical Manifestations
7.8.4. Use of Diagnostic Tests
7.8.5. Alternative Treatments

Module 8. Update on Antihemorrhagics

8.1. Antihemorrhagic Drugs

8.1.1. Definitions
8.1.2. Main Drugs
8.1.3. Mechanism of Action
8.1.4. Main Indications

8.2. Use of Vitamin K in Hemorrhagic Disorders

8.2.1. Indication of Vitamin K in Hemorrhagic Disorders
8.2.2. Pharmacokinetics and Pharmacodynamics
8.2.3. Presentation and Dosage

8.3. Coagulation Factor Concentrate

8.3.1. Therapeutic indications
8.3.2. Pharmacokinetics and Pharmacodynamics
8.3.3. Presentation and Dosage

8.4. Use of Fresh Frozen Plasma and Protamine Sulfate

8.4.1. Therapeutic indications
8.4.2. Pharmacokinetics and Pharmacodynamics
8.4.3. Presentation and Dosage

8.5. Latest Recommendations for the Use of Platelets

8.5.1. Therapeutic indications
8.5.2. Pharmacokinetics and Pharmacodynamics
8.5.3. Presentation and Dosage

8.6. Platelet Aggregation Inhibitors: The Reality of Use

8.6.1. Therapeutic indications
8.6.2. Pharmacokinetics and Pharmacodynamics
8.6.3. Presentation and Dosage

8.7. Capillary Protective and Hemostatic Vasoconstrictor Drugs

8.7.1. Therapeutic indications
8.7.2. Pharmacokinetics and Pharmacodynamics
8.7.3. Presentation and Dosage

8.8. Antifibrinolytics

8.8.1. Therapeutic indications
8.8.2. Pharmacokinetics and Pharmacodynamics
8.8.3. Presentation and Dosage

Module 9. Advances in leukemias, lymphomas and other oncohematological diseases

9.1. Hodgkin’s Lymphoma

9.1.1. Epidemiology
9.1.2. Typification and Immunophenotyping
9.1.3. Clinical Manifestations
9.1.4. Diagnosis and Staging
9.1.5. Current Treatment

9.2. Non-Hodgkin's Lymphomas

9.2.1. Epidemiology
9.2.2. Typification and Immunophenotyping
9.2.3. Clinical Manifestations
9.2.4. Diagnosis and Staging
9.2.5. Current Treatment

9.3. Acute Lymphocytic Leukemia

9.3.1. Epidemiology
9.3.2. Immunophenotype
9.3.3. Clinical Manifestations
9.3.4. Diagnosis
9.3.5. Current Treatment Alternatives

9.4. Acute Nonlymphocytic Leukemia

9.4.1. Epidemiology
9.4.2. Immunophenotype
9.4.3. Clinical Manifestations
9.4.4. Diagnosis
9.4.5. Current Treatment Alternatives

9.5. Chronic Myeloid Leukemia

9.5.1. Epidemiology
9.5.2. Immunophenotype
9.5.3. Clinical Manifestations
9.5.4. Diagnosis
9.5.5. Current Treatment

9.6. Chronic Lymphocytic Leukemia

9.6.1. Epidemiology
9.6.2. Immunophenotype
9.6.3. Clinical Manifestations
9.6.4. Diagnosis
9.6.5. Current Treatment

Module 10. Plasma Cell Dyscrasias Update

10.1. Updated Approach to the Management of Multiple Myeloma

10.1.1. Definition
10.1.2. Epidemiology
10.1.3. Clinical Manifestations
10.1.4. Diagnosis and Staging
10.1.5. Review of Treatment and New Paradigms of Autologous Transplantation

10.2. Solitary Plasmacytoma.

10.2.1. Definition
10.2.2. Epidemiology
10.2.3. Clinical Manifestations
10.2.4. Diagnosis
10.2.5. Alternative Treatments

10.3. Waldenström's Macroglobulinemia

10.3.1. Definition
10.3.2. Epidemiology
10.3.3. Clinical Manifestations
10.3.4. Diagnosis
10.3.5. New Treatments

10.4. Heavy Chain Disease

10.4.1. Definition
10.4.2. Epidemiology
10.4.3. Clinical Manifestations
10.4.4. Diagnosis
10.4.5. Treatment

10.5. Monoclonal Gammopathy of Uncertain Significance

10.5.1. Definition
10.5.2. Epidemiology
10.5.3. Clinical Manifestations
10.5.4. Diagnosis
10.5.5. New Treatments

10.6. Amyloidosis

10.6.1. Definition
10.6.2. Epidemiology
10.6.3. Clinical Manifestations
10.6.4. Diagnosis
10.6.5. Current Treatments

Module 11. New developments in general therapeutics of hematological diseases

11.1. Antineoplastic Agents

11.1.1. Groups
11.1.2. Mechanisms of action
11.1.3. Pharmacodynamics
11.1.4. Pharmacokinetics
11.1.5. Dose and Presentation
11.1.6. Adverse Effects

11.2. Treatment of Infections in Hematology Patients

11.2.1. Febrile Neutropenic Patients
11.2.2. Most frequent infections in the hematologic patient.
11.2.3. Most Frequently Used Antibiotic Treatments

11.3. Hematopoietic Progenitor Cell Transplantation

11.3.1. General Concepts
11.3.2. Indications
11.3.3. Results and Impact

11.4. Methods and Indications for Cell Therapy

11.4.1. General Concepts
11.4.2. Types of Cell Therapy
11.4.3. Indications
11.4.4. Results and Impact

11.5. Principles of Gene Therapy

11.5.1. General Concepts
11.5.2. Indications
11.5.3. Results and Future Impact

11.6. Monoclonal Antibodies in Hematological Malignancies

11.6.1. General Principles
11.6.2. Indications
11.6.3. Impact of Use

11.7. Innovative CAR-T Cell Treatment of Hematological Malignancies

11.7.1. General Principles
11.7.2. Indications
11.7.3. Impact of Use

11.8. Palliative Care for Hematology Patients

11.8.1. General Concepts
11.8.2. Treatment of the Main Symptoms in Oncohematology Patients
11.8.3. Palliative care in the end-stage patient and end-of-life care

Module 12. Update on Transfusion Medicine and Hematopoietic Cell Transplantation 

12.1. Red Blood Cell Immunology

12.1.1. General Concepts
12.1.2. Blood Groups
12.1.3. Allorecognition/Alloresponse in Transfusion

12.2. Immunology of Leukocytes, Platelets, and Plasma Components

12.2.1. General Concepts
12.2.2. Leukocyte Immunology
12.2.3. Immunology of Platelets and Plasma Components

12.3. Hemolytic Disease in Fetuses and Newborns

12.3.1. Definition
12.3.2. Epidemiology
12.3.3. Clinical Manifestations
12.3.4. Diagnosis
12.3.5. Treatment

12.4. Collection, Study, and Preservation of Blood and Blood Components

12.4.1. Methods of Obtaining Blood and Blood Derivatives
12.4.2. Preservation of Blood and Blood Derivatives
12.4.3. Care During Transport

12.5. Indications, efficacy and complications of blood, blood components and blood products transfusion.

12.5.1. General Principles
12.5.2. Indications
12.5.3. Contraindications
12.5.4. Complications

12.6. Autotransfusion

12.6.1. General Principles
12.6.2. Indications
12.6.3. Contraindications
12.6.4. Complications

12.7. Cell and Plasma Apheresis

12.7.1. General Principles
12.7.2. Types of Apheresis
12.7.3. Indications
12.7.4. Contraindications

12.8. Legislation concerning transfusion medicine

12.8.1. Ethical Aspects of Transfusion Medicine
12.8.2. Legal Aspects of Transfusion Medicine

Questo programma ti permetterà di progredire nella tua carriera in medicina trasfusionale in modo diretto ed efficace"